Glutathione-S-Transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas
- 1 December 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 11 (9) , 757-764
- https://doi.org/10.1097/00008571-200112000-00003
Abstract
Polymorphic glutathione-S-transferase (GST) genes causing variations in enzyme activity may influence individual susceptibility to lung cancer. In this case–control study (consisting of 389 Caucasian lung cancer patients, including 151 adenocarcinomas (ACs) and 172 squamous cell carcinomas (SCCs), and 353 hospital control subjects without malignant disease, genotype frequencies for GSTM1, GSTM3, GSTP1 and GSTT1 were determined by polymerase chain reaction (PCR)/ restriction fragment length polymorphism (RFLP)-based methods. While adjusted odds ratios (ORs) indicated no significantly increased risk for lung cancer overall due to any single GST genotype, the risk alleles for GSTM1, GSTM3 and GSTP1 conferring reduced enzyme activity were present at higher frequency in SCC than in AC patients. This is consistent with a reduced detoxification of carcinogenic polycyclic aromatic hydrocarbons (PAHs) from cigarette smoke that are more important for the development of SCC than for AC. An explorative data analysis also identified statistically significantly increased ORs for the combinations GSTT1 non-null and GSTP1 GG or AG for lung cancer overall (OR 2.23, CI 1.11–4.45), and for SCC (OR 2.69, CI 1.03–6.99). For lung cancer overall, and especially among SCC patients, the GSTT1 null genotype was underrepresented (SCC 11.2%v. control subjects 19%, P = 0.026, OR 0.57, CI 0.30–1.06). Additionally, in 28 patients with hamartomas, the GSTT1 null genotype was also protective (P = 0.013), while GSTP1 variant allele carriers were overrepresented (OR 2.48, CI 1.06-6.51). In conclusion, GST genotypes may act differently, either by detoxifying harmful tobacco carcinogens and/or by eliminating lung cancer chemopreventive agents. The latter role for GSTT1 would explain the observed lower risk of SCC and hamartoma associated with GSTT1 null. Further confirmatory studies are required.Keywords
This publication has 36 references indexed in Scilit:
- Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokersCancer Letters, 1999
- Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancerPharmacogenetics, 1998
- Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distributionCarcinogenesis: Integrative Cancer Research, 1998
- Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer riskCarcinogenesis: Integrative Cancer Research, 1997
- Identification of genetic polymorphisms at the glutathione S- transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancerCarcinogenesis: Integrative Cancer Research, 1997
- Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S-Transferase Pi Gene VariantsJournal of Biological Chemistry, 1997
- Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*ABiochemical Journal, 1995
- Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancerCarcinogenesis: Integrative Cancer Research, 1995
- The Glut athione S-Transferase Supergene Family: Regulation of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part ICritical Reviews in Biochemistry and Molecular Biology, 1995
- Heterogeneous expression and polymorphic genotype of glutathione S-transferases in human lung.Thorax, 1994